The Newcastle, UK-based firm, which recently expanded to Manchester, will now have a US base after the opening of an office in the Cambridge Innovation Center, Kendall Square.
The expansion has been largely funded by a six-figure investment, secured in October last year, from Fiona Cruickshank, founder of Northumberland manufacturer The Specials Laboratory.
According to ramarketing, which has contract manufacturers such as Recipharm and Sterling Pharma Solutions on its books, as well as regulatory organisations and pharmaceutical service providers, the expansion will benefit both European and US clients.
“For our EU clients, they tend to have US teams – satellite/small – or target the US, so our presence in Boston will help us to work more closely with them to develop campaigns for the North American market,” founder Raman Sehgal told us.
“For our US clients, there will be time zone benefits. We can better service them on their local time, as opposed to dealing with the 5+ hour difference!” he added.
Location, location, location
Massachusetts is one of the fastest growing hubs for pharmaceutical and biotech investment, and according to Sehgal, “one of the most exciting locations on the planet” for drug development.
The new office in Cambridge “enables us to now service North American clients locally, and have boots on the ground for our clients elsewhere in the world,” he said.
The British Consulate in New England also expressed its support of the expansion: “For the company to choose New England as its landing point in the US says a great deal about the potential for growth that exists within this market,” said Her Britannic Majesty’s Consult General to New England, Harriet Cross.
With offices now in three locations, we asked Sehgal if ramarketing is looking to expand into other geographies: “Not at the moment,” he told us, adding: “The US will be our main focus for the foreseeable. Although, the Japanese market is an interesting future prospect for us…”